Literature DB >> 25577609

Evolution and Diversity of the Human Leukocyte Antigen(HLA).

Peter V Markov1, Oliver G Pybus1.   

Abstract

Entities:  

Year:  2015        PMID: 25577609      PMCID: PMC4315060          DOI: 10.1093/emph/eou033

Source DB:  PubMed          Journal:  Evol Med Public Health        ISSN: 2050-6201


× No keyword cloud information.

Human leukocyte antigen

Human leukocyte antigen (HLA) Class I and Class II antigens can be genetically extremely diverse, play a central role in immunity and are of primary importance in several branches of medicine. By presenting fragments of pathogens or altered ‘self’ proteins, HLA molecules activate T lymphocytes and are essential in adaptive immune responses against infection or cancer. Clinically, certain HLA types are associated with severity, treatment outcomes or risk of particular infections (e.g. HIV, leprosy, hepatitis B virus) [1]. HLA are the most important histocompatibility antigens to match donors and recipients for successful organ or tissue transplantations. They are also the strongest known predictors of a range of autoimmune disorders including Type I diabetes, coeliac disease, narcolepsy and spondyloarthritis [2]. Increasing evidence also suggests that the combination of HLA types in a couple might affect fertility [3].

Evolutionary perspectives

With > 7000 alleles HLA is the most polymorphic region of the human genome [4]. The common view is that this extraordinary diversity is an evolved defence of slowly evolving vertebrates against rapidly evolving microparasites [5]. Each HLA type ‘sees’ a unique set of pathogen targets (epitopes). Individuals carrying different alleles at a given HLA locus (heterozygotes) produce both molecules thereby increasing the number of potentially targeted epitopes and so, on average enjoy broadened immunity and likely stronger protection [5]. Such advantage means that everything else being equal, heterozygosity at HLA loci will be favoured by natural selection. Furthermore, when evolving pathogens infect HLA-heterogeneous populations they are forced to adapt de novo each time they transmit. This hinders the adaptation of pathogens to the population of hosts as a whole and also favours in hosts many, rare HLA alleles [5]. HLA diversity is further promoted through reproductive mechanisms. Evidence from studies in animals and humans indicates bias in mate choice towards partners carrying major histocompatibility complex (MHC) or HLA alleles that are rare and/or dissimilar from the individual’s own. Couples more discordant in their HLA alleles were shown to be more fertile [3]. Such behavioural and reproductive phenomena may be selectively favoured if they increase HLA diversity of offspring.

Future implications

Studies of HIV and Hepatitis C virus suggest that rapidly evolving RNA viruses are able to escape HLA-dependent defences in human populations [6]. HLA is a major determinant of viral persistence and severity while many current vaccine efforts employ HLA-restricted immune responses. Thereby proper understanding of virus-HLA coevolution is instrumental for making informed treatment and vaccine-design decisions for a range of major chronic and acute infections. Given the frequency-dependent protection of HLA, populations where particular HLA types are very common (e.g. A*2301 in West Africa) could potentially be identified as hot spots for severe disease, endemic persistence or pathogen emergence.
  6 in total

Review 1.  Status report from 'double agent HLA': health and disease.

Authors:  Philip Dyer; Roger McGilvray; Victoria Robertson; David Turner
Journal:  Mol Immunol       Date:  2012-10-07       Impact factor: 4.407

Review 2.  Studies of HLA, fertility and mate choice in a human isolate.

Authors:  C Ober
Journal:  Hum Reprod Update       Date:  1999 Mar-Apr       Impact factor: 15.610

3.  Adaptation of HIV-1 to human leukocyte antigen class I.

Authors:  Yuka Kawashima; Katja Pfafferott; John Frater; Philippa Matthews; Rebecca Payne; Marylyn Addo; Hiroyuki Gatanaga; Mamoru Fujiwara; Atsuko Hachiya; Hirokazu Koizumi; Nozomi Kuse; Shinichi Oka; Anna Duda; Andrew Prendergast; Hayley Crawford; Alasdair Leslie; Zabrina Brumme; Chanson Brumme; Todd Allen; Christian Brander; Richard Kaslow; James Tang; Eric Hunter; Susan Allen; Joseph Mulenga; Songee Branch; Tim Roach; Mina John; Simon Mallal; Anthony Ogwu; Roger Shapiro; Julia G Prado; Sarah Fidler; Jonathan Weber; Oliver G Pybus; Paul Klenerman; Thumbi Ndung'u; Rodney Phillips; David Heckerman; P Richard Harrigan; Bruce D Walker; Masafumi Takiguchi; Philip Goulder
Journal:  Nature       Date:  2009-02-25       Impact factor: 49.962

Review 4.  Human genetic susceptibility to infectious disease.

Authors:  Stephen J Chapman; Adrian V S Hill
Journal:  Nat Rev Genet       Date:  2012-02-07       Impact factor: 53.242

5.  The importance of immune gene variability (MHC) in evolutionary ecology and conservation.

Authors:  Simone Sommer
Journal:  Front Zool       Date:  2005-10-20       Impact factor: 3.172

6.  The IMGT/HLA database.

Authors:  James Robinson; Jason A Halliwell; Hamish McWilliam; Rodrigo Lopez; Peter Parham; Steven G E Marsh
Journal:  Nucleic Acids Res       Date:  2012-10-17       Impact factor: 16.971

  6 in total
  2 in total

1.  Comprehensive Analysis of Cytomegalovirus pp65 Antigen-Specific CD8+ T Cell Responses According to Human Leukocyte Antigen Class I Allotypes and Intraindividual Dominance.

Authors:  Seung-Joo Hyun; Hyun-Jung Sohn; Hyun-Joo Lee; Seon-Duk Lee; Sueon Kim; Dae-Hee Sohn; Cheol-Hwa Hong; Haeyoun Choi; Hyun-Il Cho; Tai-Gyu Kim
Journal:  Front Immunol       Date:  2017-11-21       Impact factor: 7.561

2.  Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link.

Authors:  Huyen Nguyen; Christian Wandell Thorball; Jacques Fellay; Jürg Böni; Sabine Yerly; Matthieu Perreau; Hans H Hirsch; Katharina Kusejko; Maria Christine Thurnheer; Manuel Battegay; Matthias Cavassini; Christian R Kahlert; Enos Bernasconi; Huldrych F Günthard; Roger D Kouyos
Journal:  Elife       Date:  2021-06-01       Impact factor: 8.140

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.